Clincosm LogoSign in Get a demo

metastatic triple negative breast cancer

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer Trial in Worldwide (Talimogene Laherparepvec,

Completed
Has Results
  • Metastatic Triple Negative Breast Cancer
  • Metastatic Colorectal Cancer
  • Talimogene Laherparepvec
  • Atezolizumab
  • Los Angeles, California
  • +16 more
Nov 22, 2022

Metastatic Triple Negative Breast Cancer Trial in Worldwide (Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg

Active, not recruiting
Has Results
  • Metastatic Triple Negative Breast Cancer
  • Olaparib Continuous (28-Day cycle) 300 mg BD.
  • +2 more
  • Birmingham, Alabama
  • +140 more
Nov 17, 2022

Metastatic Triple Negative Breast Cancer Trial in New Haven (Tumor infiltrating lymphocytes (TIL) LN-145)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • Tumor infiltrating lymphocytes (TIL) LN-145
  • New Haven, Connecticut
    Yale School of Medicine
Jul 20, 2022

Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • PLD Chemotherapy
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 23, 2022

Metastatic Triple Negative Breast Cancer Trial in Birmingham (Combination of Veliparib + Lapatinib)

Active, not recruiting
  • Metastatic Triple Negative Breast Cancer
  • Combination of Veliparib + Lapatinib
  • Birmingham, Alabama
    University of Alabama at Birmingham
Feb 25, 2022

Metastatic Triple Negative Breast Cancer Trial (Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy

Withdrawn
  • Metastatic Triple Negative Breast Cancer
  • (no location specified)
Jan 24, 2022

Metastatic Triple Negative Breast Cancer Trial (pembrolizumab, capecitabine, eribulin)

Completed
Has Results
  • Metastatic Triple Negative Breast Cancer
  • pembrolizumab
  • +4 more
  • (no location specified)
Nov 9, 2021

Metastatic Triple Negative Breast Cancer Trial in Houston (L-NMMA, Docetaxel, Amlodipine)

Completed
  • Metastatic Triple Negative Breast Cancer
  • Houston, Texas
    Houston Methodist Hospital
Oct 12, 2021

Metastatic Breast Cancer, Metastatic Triple Negative Breast Cancer Trial in Worldwide (Combination therapy (S81694 + paclitaxel)

Completed
  • Metastatic Breast Cancer
  • Metastatic Triple Negative Breast Cancer
  • Combination therapy (S81694 + paclitaxel) phase I
  • +2 more
  • Bruxelles, Belgium
  • +5 more
May 20, 2021

Metastatic Triple Negative Breast Cancer, Safety Issues, Efficacy Trial in Assiut (Bevacizumab)

Completed
  • Metastatic Triple Negative Breast Cancer
  • +2 more
  • Assiut, Assuit, Egypt
    Clinical Oncology Departement Assuit University Hospital
Mar 7, 2021

Metastatic Triple Negative Breast Cancer Trial (Atezolizumab, Bevacizumab, Gemcitabine)

Not yet recruiting
  • Metastatic Triple Negative Breast Cancer
  • (no location specified)
Feb 1, 2021

Metastatic Triple Negative Breast Cancer Trial in Guangzhou (TPC, Bicalutamide 150 mg)

Terminated
  • Metastatic Triple Negative Breast Cancer
  • TPC
  • Bicalutamide 150 mg
  • Guangzhou, Guangdong, China
  • +1 more
Jan 26, 2021

Metastatic Triple Negative Breast Cancer Trial in Cleveland (Carboplatin, Nab-paclitaxel, Pembrolizumab)

Active, not recruiting
  • Metastatic Triple Negative Breast Cancer
  • Cleveland, Ohio
  • +1 more
Dec 14, 2020

Metastatic Triple Negative Breast Cancer Trial in Calgary (Trifluridine/Tipiracil)

Withdrawn
  • Metastatic Triple Negative Breast Cancer
  • Calgary, Alberta, Canada
    Tom Baker Cancer Centre
Jun 9, 2020

Metastatic NSCLC, Metastatic Colon Cancer, Metastatic Triple Negative Breast Cancer Trial in Goodyear (CTLA-4 Antibody,

Withdrawn
  • Metastatic Non-Small Cell Lung Cancer
  • +2 more
  • CTLA-4 Antibody
  • Hypofractionated Radiotherapy
  • Goodyear, Arizona
    Western Regional Medical Center
Jun 23, 2017

Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer Trial in Nashville (NK012 and carboplatin)

Completed
  • Advanced Solid Tumors
  • Metastatic Triple Negative Breast Cancer
  • NK012 and carboplatin
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Nov 12, 2014